A-790742 is a potent human immunodeficiency virus type 1 (HIV-1) protease inhibitor with an 24 EC 50 value ranging between 2 and 7 nM against wild-type HIV-1. The activity of this 25 compound is lowered by approximately 7-fold in the presence of 50% human serum. A-790742 26 maintained potent antiviral activity against lopinavir-resistant variants generated in vitro as 27 well as a panel of molecular clones containing proteases derived from HIV-1 patient isolates 28 with multiple protease mutations. During in vitro selection, A-790742 selected two primary 29 mutations (V82L and I84V) along with L23I, L33F, K45I, A71V/A, and V77I in the pNL4-3 30 background, and two other mutations (A71V and V82G) accompanied by M46I and L63P in 31
when analyzed in an in vivo model for hyperlipidemia associated with PI therapy (7, 21, 40) . 61
In this study, we characterized A-790742 in a tissue culture system against wild type (WT) and 62 mutant HIV-1 viruses. In addition, we performed in vitro selection and characterization of A-63 790742 resistant variants using two different HIV-1 strains. Finally, we describe the results of 64 cross-resistance studies of A-790742 resistant variants with commercially available PIs. 65
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Generation of HIV-1 resistant to A-790742 by in vitro selection 67
Generation of resistant virus by in vitro passages has been described previously (2, 4, 9, 25, 27, 68 35) . Briefly, 2x10 6 MT-4 cells were infected with WT HIV-1 strains pNL4-3 or RF separately 69 at a multiplicity of infection (MOI) of 0.003 for 2 hours, washed, and then cultured in the 70 presence of A-790742 at an initial concentration of 1.4 nM. Viral replication was monitored by 71 determination of p24 antigen levels in the culture supernatants by ELISA every 3-4 days. 72
When p24 antigen levels exceeded 10 ng/ml, the viral supernatants were filtered and used to 73 infect fresh MT-4 cells in the presence of an increasing concentration of A-790742, leading to 74 the generation of virus with increased resistance to A-790742. Samples of viral supernatants 75 from each passage were frozen at -80ºC for later analyses. 76
Titration, EC 50 and TD 50 determination using MTT assay 77
All viruses used for the MTT assay were titered by infecting 2x10 5 MT-4 cells for 1 hr at 37ºC 78 with serial half-log dilutions of virus. Following infection, cells were washed and plated into a 79 96-well plate at a concentration of 10 4 cells per well in the presence of 0.5% dimethyl sulfoxide 80 (DMSO). Five days post-infection, the level of virus-induced cytopathic effect (CPE) was 81 measured using an MTT colorimetric assay (2, 12, 16, 31) and the tissue culture infectious 82 dose (TCID 50 ) of each virus was calculated using the Sperman-Karber method. 83
For 50% effective concentration (EC 50 ) determinations, 10 6 MT-4 cells were infected with viral 84 stock at an MOI of 0.003 (2, 16, 27, 29, 31) with inhibitors relative to that of the untreated cells was calculated. EC 50 values were 128 determined using Prism software (11, 30, 33) . Replication capacities (RC) of mutant constructs 129 were calculated by comparing the luciferase activity generated by mutant to that generated by 130 the WT. The RC values were expressed as percentages of the replication of the WT construct. 131
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on October 2, 2017 by guest http://aac.asm.org/ Downloaded from viruses were highly resistant to LPV, with 59-to more than 500-fold reduction in susceptibility 156 relative to the WT virus (2, 27). Taken together, A-790742 displayed anti-HIV activity 157 superior to LPV, ATV, DRV and TPV for WT pNL4-3 and RF, as well as LPV-resistant HIV-158 1 mutants. 159 Antiviral activity of A-790742 against HIV-1 molecular clones with protease genes 160 derived from patient isolates 161
To determine if A-790742 could effectively inhibit different PI resistant viruses, it was tested 162 along with LPV and ATV in single cycle assays against HIV molecular clones containing 163 protease genes derived from HIV-1 isolates from patients who failed different PI treatments 164 (Table 3 ). The first three constructs in Table 3 were derived from samples from patients who  165 failed LPV treatment. The rest of the constructs were from a panel of molecular clones 166 displaying reduced susceptibility to more than one PI. Each of these tested isolates contained a 167 mixture of primary and secondary mutations as designated by the International AIDS Society-168 USA-resistance panel (11, 13) . In general, all clones were less resistant to A-790742 than LPV 169 and ATV. A-790742 was active against clones with V82A/F/T mutations. However, combined 170 mutations at positions 71 and 84 appeared to confer some degree of resistance to A-790742. Of 171 note, mutations at positions 71 and 84 were selected during the passage of pNL4-3 in the 172 presence of A-790742 as described below. Other secondary mutations also contributed to the 173
generation of resistance to all tested PIs. 174
Selection of A-790742 resistant virus by in vitro passages 175
In order to understand the importance of genetic background in the selection of viruses 176 resistant to A-790742, two different strains of HIV-1 (pNL4-3 and RF) were passaged in the 177 monitored every 3-4 days by detection of viral antigen (p24) before increasing the 179 concentration of the inhibitor. pNL4-3 and RF were initially grown in the presence of 1.4 nM 180 A-790742 (1/2 EC 50 value for pNL4-3 and ¼ EC 50 value for RF virus). There was also an 181 attempt to grow RF virus at an initial concentration of 3 nM A-790742 (1/2 EC 50 value), but 182 viral replication was very low (data not shown). During the selection process, the A-790742 183 concentration was increased gradually to a final concentration of 2 µM (pNL4-3) ( Table 4) or 184 0.5 µM (RF) ( Table 5 ). It took approximately three and half months to complete the selection. 185
The selection with pNL4-3 progressed faster than with RF virus. A total of twenty-one 186 passages were performed for pNL4-3, but only fifteen passages for RF. This difference might 187 be due to the different genetic backgrounds of the two viruses, and suggests that resistance in 188 the RF background developed less rapidly than in the pNL4-3 background. 189
Sequence analyses of the protease-coding region from HIV-1 passaged in A-790742 190
To monitor the protease mutations selected by A-790742, RNA was isolated from the culture 191 supernatant of passages 5, 6, 7, 8, 9, 10, 13, 15, 18 and 21 for pNL4-3 selection (Table 4) , as 192 well as from those of passages 6, 8, 10, 13 and 15 for RF selection (Table 5 ). The RNA was 193 amplified by RT-PCR and nested PCR, and then the population sequences of the PCR products 194 were determined. In the selection with pNL4-3, two primary mutations were initially observed : 195 I84V (passages 5, 6, 7, 8, 9, 10 and 13) and V82L (passages 8, 9,10 and 13). These two 196 mutations were also detected in passages 15, 18 and 21, suggesting that they were important 197 for the generation of viral resistance. In passages 15, 18 and 21, additional mutations L23I, 198 L33F, K45I, A71V and V77I were also detected. The A-790742 resistance selection using RF 199 virus produced a different pattern of mutations. The mutation V75I was found in passage 8, but 200 were determined using an MTT assay (Table 6 ). Virus from pNL4-3 passage 9 was 12.7-fold 210 less susceptible to A-790742 than the WT pNL4-3 virus. This passage was the most resistant to 211 RTV, with a 26.7-fold increase in its EC 50 value as compared to the WT pNL4-3 virus. ATV, 212 LPV, SQV, APV, IDV, and NFV demonstrated 3-to 9-fold increases in their EC 50 values at 213 passage 9. Virus selected in pNL4-3 passage 15 had a similar level of resistance to A-790742 214 and RTV, with a 28-fold change in EC 50 value. In addition, ATV and APV had 13.6-and 10.5-215 fold changes in their respective EC 50 s to virus from passage 15. LPV, SQV, IDV and NFV had 216 about 5-to 6-fold change in their EC 50 values with this passaged virus. pNL4-3 passage 21 217 virus had the highest degree of resistance to all tested PIs. It was highly resistant to A-790742 218 (>2500-fold resistance), RTV (>141-fold resistance), ATV (145-fold resistance) and NFV 219 (>93-fold resistance). However, it had only a low to moderate level of resistance to the other 220 tested PIs. In particular, it retained most of its sensitivity to SQV, LPV and IDV. 221
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on October 2, 2017 by guest http://aac.asm.org/ Downloaded from EC 50 values with this passaged virus. In addition, the passage 13 virus displayed the greatest 225 resistance to LPV, with >301-fold increase in its EC 50 value, and was the least resistant to 226 SQV, with a 21-fold increase in its EC 50 value as compared to the WT RF virus. 227
Phenotypic analyses of HIV-1 molecular clones resistant to A-790742 228
To determine the effect of genotypic changes found in the passaged variants on the 229 susceptibility of HIV-1 to A-790742 and commercially available PIs, HIV-1 molecular clones 230 with protease mutations selected by A-790742 in pNL4-3 and RF were engineered in the 231 pNL4-3-Luc vector (Table 7) . These constructs permitted rapid and sensitive quantification of 232 drug susceptibility during a single round of viral replication in the presence of increasing 233 concentration of drugs (30, 33) . 234
Molecular clones containing the single mutation V82L or I84V in the pNL4-3 background 235 displayed resistance only to A-790742 and RTV (Table 7) . In particular, clone 1, which 236 contained an I84V mutation, was 2-and 3-fold less susceptible to A-790742 and RTV, 237 respectively, as compared to the WT pNL4-3-Luc. In contrast, clone 2, which harbored a V82L 238 mutation, displayed 22-fold resistance to A-790742, but only 7-fold resistance to RTV. Mutant 239 clone 3, which had secondary mutations L33F and K45I in addition to primary mutations V82L 240 and I84V, was 23-fold less susceptible to A-790742. Clone 3 was more resistant than clone 2 241 to all other tested PIs except SQV (Table 7) . Clone 4 contained secondary mutations L33F, 242 A71V, G73S and V77I in addition to primary mutations V82L and I84V. Mutations L33F, 243 A71V, and V77I were secondary mutations detected by population sequencing in the passaged 244 variants (Table 4) . However, G73S was not detected by population sequencing, but was 245 identified by sequencing individual TA clones derived from pNL4-3 passaged in the presence 246
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on October 2, 2017 by guest http://aac.asm.org/ Downloaded from less resistant to all tested PIs than clone 3 (Table 7) . The difference in the resistance profiles of 248 clone 3 and 4 suggests that K45I is important for the resistance to all PIs except A-790742 and 249 SQV. Furthermore, individual or combined A71V, G73S and V77I mutations contributed to 250 the increase in resistance to A-790742. Among these 3 mutations, A71V was detected in both 251 pNL4-3 and RF after selection using A-790742, and probably contributed most of the 252 additional resistance to A-790742. It is of note that molecular clone 3, which contained most of 253 the mutations of passaged HIV-1 P21 (Table 6 ), showed the same trend of resistance as P21. 254
Both clone 3 and P21 were more resistant to A-790742, ATV and RTV than the other tested 255
PIs. 256
Clone 5, which contained A-790742 selected PI mutations in the RF background, was also 257 evaluated in the single cycle assay (Table 7) . This clone contained the primary mutation V82G 258 and other mutations L63P and A71V. It was 72-fold less susceptible to A-790742 than the WT 259 construct, and highly resistant to LPV and RTV, with more than 1300-fold resistance to these 260 two PIs. However, it had only moderate levels of resistance to the other tested PIs. Importantly, 261 it was only 28 times more resistant to SQV than the WT construct. Interestingly, this construct 262 conferred overall a higher level of resistance to all tested PIs than all molecular clones in the 263 pNL4-3 background (Clones 1, 2, 3 and 4, Table 7 ). 264
During phenotypic testing, significant differences in replication efficiencies between molecular 265 clones with wild-type and mutant protease genes in the RF background were observed (Figure  266 2). Constructs with the combined mutations L63P, A71V, and V82G or M46I, A71V, and 267 V82G replicated 99% less efficiently than the wild-type HIV-RF-luc construct based on the 268 difference in luciferase signal. The luciferase signal of the RF molecular clone harboring the 269 from PI-resistant patient isolates (Table 3) , we speculate that A-790742 is likely to retain most 291 of its antiviral activity against patient isolates with multiple mutations in the protease gene. 292
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Multiple combinations of mutations could confer resistance to A-790742, but their degree of 293 resistance to A-790742 appeared to be less than that to LPV and ATV. In particular, patient 294 isolates with mutations A71V combined with I84V displayed resistance to A-790742, whereas 295 mutations V82A/F/T did not seem to confer much resistance to A-790742 (Table 3 ). Consistent 296 with these results, mutations A71V and I84V were also detected in selection of resistant 297 viruses with pNL4-3 in the presence of A-790742 in vitro (Table 4) . 298
on October 2, 2017 by guest http://aac.asm.org/ Downloaded from mutant viruses in two different genetic backgrounds with this PI. Passage in a pNL4-3 300 background initially selected the I84V mutation (Table 4) . Further passages selected an 301 additional primary mutation V82L (passage 8), and a number of other mutations, e.g. A71V, in 302 later passages. In contrast, the V75I mutation was first detected in the selection in the RF 303 background (Table 5 ). However, the combination of A71V and V82G mutations was later 304 observed in the RF selection at passage 10, accompanied by the appearance of other mutations 305 in passage 13. In two studies conducted previously, passage of viruses in the presence of LPV 306 in a pNL4-3 background resulted in the selection of mutant viruses with different mutation 307 patterns including primary mutations I84V and I50V/M46I (2, 27). 308
The selection of different major mutations with A-790742 in different strains of HIV-1 points 309 to the importance of genetic background for selection of resistant mutants. In addition, the 310 selection with pNL4-3 progressed faster than with RF virus in the presence of A-790742, 311
suggesting that resistance developed more readily in the pNL4-3 than the RF background. 312
Slower selection with the RF than with the pNL4-3 strain is consistent with the observation 313 that molecular clones with the RF protease gene containing mutations A71V plus V82G had 314 greatly reduced replication capacities compared to the molecular clone containing the wild-315 type RF protease (Figure 2) . Our results are consistent with previous reports demonstrating that 316 the development of resistance was affected by the viral strain used in the selection (4, 9). 317
Primary mutations V82L and V82G are not commonly selected with existing PIs. The single 318 mutation V82L (clone 2, Table 7 ), and probably the V82G mutation, did not confer a 319 significant degree of resistance to A-790742. In contrast, mutants harboring V82L or V82G, in 320 combination with other mutations, e.g. A71V, were highly resistant to A-790742. These 321
on October 2, 2017 by guest http://aac.asm.org/ Downloaded from mutants were mainly cross-resistant to RTV and LPV as well as ATV (Tables 6 and 7) . 322 However, they were only moderately resistant to most other tested PIs, and remained quite 323 susceptible to SQV, APV, IDV, DRV and TPV. 324
In summary, A-790742 displays favorable anti-HIV-1 potency against both WT and most PI-325 resistant mutants. In vitro passage of HIV-1 with A-790742 led to the selection of the primary 326 mutation I84V, as well as the uncommon mutations V82L and V82G in protease. Molecular 327 clones harboring these primary mutations, in combination with other mutations, were highly 328 resistant to A-790742, as well as to LPV and RTV. These clones, however, were only 329 moderately resistant to most other PIs and retained their susceptibility to SQV. In addition, 330 mutation V82G in the RF background appeared to have a significant negative impact on the 331 replication capacity of the virus. A-790742 thus has promising antiviral activity and a 332 potentially advantageous resistance profile. 333
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The RC values were expressed as percentages of the WT and reflected the levels of 573 replication for mutant clones compared to that of the WT control. Replication 574 capacity of WT pNL4-3-Luc molecular clone was approximatly two times higher 575 than WT RF-Luc molecular clone. Black boxes represent pNL4-3 and pNL4-3-576 I84V  V82L  L33L,  K45I,  V82L, I84V   L33L,  A71V,  G73S,  V77I,  V82L, I84V   RF-Luc  L63P,  A71V,  V82G, M46I, A71V, V82G, 
